Stockreport

Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update

Rani Therapeutics Holdings, Inc. - Class A  (RANI) 
PDF - Completed two equity offerings with total gross proceeds of approximately $20.0 million; cash runway extended into 3Q 2025 - - Announced new preclinical pharmacok [Read more]